MEI Pharma Inc: to Prioritize Clinical Development of Voruciclib While Enabling Development of a New Me-344 Formulation for Phase 1 Study
MEI Pharma Inc:優先考慮Voruciclib的臨床開發,同時支持爲1期研究開發新的ME-344配方
MEI Pharma Inc: to Prioritize Clinical Development of Voruciclib While Enabling Development of a New Me-344 Formulation for Phase 1 Study
MEI Pharma Inc:優先考慮Voruciclib的臨床開發,同時支持爲1期研究開發新的ME-344配方
使用瀏覽器的分享功能,分享給你的好友吧